NCT05005754 is a NA clinical trial of Probiotics in Cardiometabolic Risk Factors, sponsored by Sun Yat-sen University.

Who is sponsoring NCT05005754?

NCT05005754 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT05005754?

Interventions in NCT05005754: Probiotics, Placebo control.

What condition does NCT05005754 study?

NCT05005754 studies Cardiometabolic Risk Factors.

Is NCT05005754 still recruiting?

NCT05005754 is currently completed. Last updated 5 May 2022.

Last reviewed 2022-05-05 · How we verify

NCT05005754

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Probiotics on Cardiometabolic Health

Completed NA Last updated 5 May 2022

What this trial tests

NA trial testing Probiotics in Cardiometabolic Risk Factors in 130 participants. Completed in 28 February 2022.

Timeline

1 September 2021

Primary endpoint
28 February 2022

28 February 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	130
Start date	1 September 2021
Primary completion	28 February 2022
Estimated completion	28 February 2022
Sites	2 locations across China

Drugs / interventions tested

Probiotics — full drug profile →
Placebo control

Conditions studied

Cardiometabolic Risk Factors — all drugs for Cardiometabolic Risk Factors →

Sponsor

Sun Yat-sen University

Who can join

Adults 30 to 60, any sex, with Cardiometabolic Risk Factors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms. This trial aims to examine its protective effect in humans.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiometabolic benefits of Lacticaseibacillus paracasei 8700:2: A randomized double-blind placebo-controlled trial.
Yang J, Huang J, Huang Z, Xu Y, et al · · 2023 · cited 6× · PMID 37506599 · DOI 10.1016/j.clnu.2023.07.017
Interaction Between Microbiota and Immunity: Molecular Mechanisms, Biological Functions, Diseases, and New Therapeutic Opportunities.
Zeng J, He Z, Wang G, Ma Y, et al · · 2025 · cited 5× · PMID 40547945 · DOI 10.1002/mco2.70265

Verify or expand the search:

Other trials of Probiotics

Trials testing the same drug.

NCT07470645 — Effects of Probiotic Supplementation on Stress and Anxiety in Students · NA · not yet recruiting
NCT06943235 — Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in th · Phase 2 · recruiting
NCT06827964 — Practice of Nutrition Package in Myanmar · NA · not yet recruiting
NCT06873165 — Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to C · NA · recruiting
NCT06583720 — Comparative Study Between Photodynamic Therapy with LED Associated with Probiotics in the Treatment of Halitosis · Phase 1 · recruiting

Other recruiting trials for Cardiometabolic Risk Factors

Currently open trials in the same condition.

NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
NCT07363616 — Pilot Test of Five Weight Neutral Interventions to Improve Health Among Adults of Higher Body Weight · NA · recruiting
NCT07053657 — Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight/Obesity Adolescents in China · NA · recruiting
NCT07513168 — Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults · Phase 4 · recruiting
NCT06775132 — Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05005754 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 5 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05005754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing